Drugs / AMT-116
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05725291 | Jul 2023 → Dec 2026 expected | neoplasm | Multitude Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07590531 | Jun 2026 → May 2027 expected | non-small cell lung carcinoma | Multitude Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06782334 | May 2024 → Jun 2026 overdue | cancer | Multitude Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMT-116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05725291 ↗ |
| Modality | Other / unclassified | “AMT-116 is an antibody Drug Conjugate (ADC)” NCT07590531 ↗ |
| Route | Intravenous | “Administered intravenously” NCT05725291 ↗ |